SHRX — Sharp Therapeutics Share Price
Last trade - 00:00- CA$15.81m
- CA$15.70m
- 35
- 15
- 74
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 245.51 | ||
| Price to Tang. Book | 245.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -639.59% | ||
| Return on Equity | -165% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sharp Therapeutics Corp. is a preclinical therapeutics company engaged in the discovery and development of small-molecule therapies for the treatment of genetic diseases. It uses a collection of platform technologies to discover compounds that can restore the function lost in mutation, thus restoring the patient to normality. The components of this technology platform are the CoreX assay technology, which enables measurements of the loss-of-function associated with gene mutation in a particular disease; the AlloChem Compound Libraries, that have been curated from commercial compound libraries for their ability to bind the target protein in an allosteric manner, thus increasing its stability and activity at the same time, and the Mine data system and machine learning layer, which combines data from various compounds and programs to provide models for what compounds should be made during medicinal chemistry and to improve the data quality of the signals coming from the CoreX assays.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- October 4th, 2021
- Public Since
- August 4th, 2023
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 8,545,200
- Address
- 2403 Sidney St, Suite 264, PITTSBURGH, 15203
- Web
- https://www.sharptx.com/
- Phone
- +1 4122065303
- Auditors
- MNP LLP
Similar to SHRX
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
As of Today at 23:10 UTC, shares in Sharp Therapeutics are trading at CA$1.85. This share price information is delayed by 15 minutes.
Shares in Sharp Therapeutics last closed at CA$1.85 and the price had moved by +76.19% over the past 365 days. In terms of relative price strength the Sharp Therapeutics share price has outperformed the Toronto Stock Exchange 300 Composite Index by +56.64% over the past year.
There is no consensus recommendation for this security.
Find out moreSharp Therapeutics does not currently pay a dividend.
Sharp Therapeutics does not currently pay a dividend.
Sharp Therapeutics does not currently pay a dividend.
To buy shares in Sharp Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$1.85, shares in Sharp Therapeutics had a market capitalisation of CA$15.81m.
Here are the trading details for Sharp Therapeutics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: SHRX
Based on an overall assessment of its quality, value and momentum Sharp Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sharp Therapeutics. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +75.16%.
As of the last closing price of CA$1.85, shares in Sharp Therapeutics were trading +1.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sharp Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$1.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Sharp Therapeutics' directors